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PARALLEL OPPOSED EDITORIAL

MR‐linac is the best modality for lung SBRT
1 | INTRODUCTION
during treatment delivery, comfort, and accuracy. These advanThe introduction of MR‐linac hybrid modality started a new era in

tages would beneﬁt any patient undergoing radiotherapy, but pro-

image guidance for radiotherapy. It provides superior soft tissue con-

vide speciﬁc gains for lung SBRT patients. Clinical trials have

trast compared to conventional x‐ray imaging, and offers the ability

shown lung SBRT already achieves 98% tumor control, however

to track and gate treatment delivery, yet challenges and limitations

there is still a 17% risk of grade 3–4 toxicity4 and it requires

1

remain in various aspects. Our previous Parallel Opposed issues dis-

oppressive patient immobilization. The fast‐growing number of

cussed the additional physicist qualiﬁcation and residency require-

patients eligible for lung SBRT further presses the need for tech-

ments for the use of MRI in radiotherapy settings.2,3 Herein, we

nological improvement. The MR‐linac tracking and accuracy reduce

continued our discussion on the clinical use of MR‐linac and its

the volume of normal lung and chest wall irradiated, decreasing

potential improvement in treatment efﬁcacy for lung stereotactic

toxicity, and obviating the need for immobilization.

body radiotherapy (SBRT). Dr. Andrew Godley believes that “MR‐li-

MR‐linac provides the best targeting of any system available as it

nac is the best modality for lung SBRT,” while Dr. Dandan Zheng

directly images the tumor throughout treatment delivery. The rea-

explained her doubts and concerns.

sons are four‐fold: First, 2D cine‐MRI based tumor tracking enables

Dr. Andrew Godley received his Ph.D. in High Energy Physics

gating directly on the tumor position relative to the planned position.

from the University of Sydney in 2001. Dr Godley continued in par-

This cine imaging incurs no additional radiation exposure. Although

ticle physics at the University of South Carolina and Fermilab, until

some conventional systems acquire planar imaging during treatment,

2007 when he trained in medical physics at the Medical College of

the radiation dose over a large area would be excessive to achieve

Wisconsin. Dr. Godley spent 7 years as a staff physicist at the

the continuous monitoring of the MR‐linac. Second, while using

Cleveland Clinic before joining the Miami Cancer Institute in 2018

external surrogates facilitates continuous monitoring, these surro-

to help develop their MR‐linac and SBRT programs.

gates require at least an additional 1 mm margin to ensure correla-

Dr. Dandan Zheng received her Ph.D. in Applied Science from

tion with the tumor.5 Third, the precise gating window of the MR‐

the University of California Davis in 2007. After conducting a post-

linac provided by its continuous tumor tracking limits or eradicates

doctoral training in Radiation Oncology at Virginia Commonwealth

multileaf collimator (MLC) interplay issues, which was reported to

University, she joined the department as an assistant professor in

affect delivery accuracy of other modalities6 and thus reduce target

2009. In 2012 Dr. Zheng moved to University of Nebraska Medical

coverage.7 Lastly, the tumor based gating eliminates the need to

Center where she is currently an associate professor and the medical

deﬁne an internal target volume (ITV), which is conventionally used

physics residency program director.

Dr. Zheng is an avid peer

to ensure tumor coverage during the breathing cycle, but increases

reviewer/associate editor for many journals, and her research inter-

the volume of normal lung irradiated. Further, traditional ITVs are

ests include image guidance, radiomics and machine learning, stereo-

just a snapshot of tumor motion observed over tens of seconds in a

tactic RT, dose algorithms, and motion management.

4D CT. When compared to a treatment length cine‐MRI based ITV,
the four‐dimensional computed tomography (4D CT) based ITV typi-

2 | OPENING STATEMENT
2.A | Dr. Andrew Godley

cally captures only 45%–90% of the required volume,8 leading to
potential under dosing. The MR‐linac continuous tracking accounts
for the breathing motion including large excursions of the tumor, so
that this motion does not have to be forcibly limited.

One vision of future radiotherapy is for patients to arrive for

With the above‐mentioned target monitoring and tracking, immo-

treatment, lie down on the couch, and the treatment system to

bilization for MR‐linacs does not then feature compression or breath

automatically locate and irradiate their tumor, regardless of its

control, leading to higher patient comfort during treatment. Due to

position or motion, sparing all but the surrounding few millimeters

the continuous imaging of the tumor, the patient can be coached by

of normal tissue. The hybrid technology of MR‐guided linear accel-

the therapists during treatment, or even see and respond to their

erator is today's embodiment of that vision. It provides three main

own cine‐MRI, in order to achieve optimal breath holds. By consis-

advantages to patients: monitoring the actual tumor location

tently placing the tumor in the gating window, the gating duty cycle
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is increased and treatment times reduced. Video feedback for

feasible after decades of R&Ds, the linac component in an MR‐linac

breath‐hold delivery has been positively viewed by patients treated

is still not up to the highest standard of modern linacs. The essential

on the MR‐linac.9 Commonly no immobilization is necessary, with

technologies pertaining to treatment time reduction for lung SBRT,

the patient arranged comfortably on the couch. No implanted ﬁdu-

such as volumetric modulated arc therapy (VMAT) and high dose

cials are required either, making for a safer and noninvasive treat-

rates (up to 2400 MU/min),19,20 are not available on the MR‐linac.

ment. This increased patient comfort is achieved without limiting the

Currently, the MR‐linac is only capable of step‐and‐shoot, low dose

accuracy of the MR‐linac.

rate (450 MU/min for Elekta Unity or 600 MU/min for ViewRay

The MR‐linac allows several other major improvements in terms of

MRIdian), low gantry speed, and low MLC speed, all of which sub-

accuracy in planning and treatment. The treatment planning algorithm

stantially lengthen the treatment duration. This prolonged treatment

used for MR‐linac planning has always been based on Monte Carlo

time poses contraindication for patients who cannot tolerate due to

simulation, which provides a more accurate dose estimation than used

back pain or poor performance status, and increases treatment varia-

10

In addition, the pre-

tions and motion uncertainty. In addition, the MR‐linac has a limited

treatment volumetric MR imaging can be acquired in 17 s, not only

lateral range of isocenter and forces off‐axis geometry for those

does this make for an easier breath hold than for current cone‐beam

tumors located outside the range. This can potentially lead to exces-

CTs, but it also reduces averaging of the tumor due to motion from

sive monitor units and hence high integral dose to normal tissue.21

repeated or longer breath holds. This leads to more accurate alignment

The couch correction range is also limited with no option of couch

of the patient in the MR‐linac. Furthermore, the minimum 4 Hz rate of

rotation and, in some models, lateral translation. Furthermore, the

cine‐MRI allows for the capture of cardiac derived tumor motion for

electron return effect is much more pronounced in lung and can lead

central lesions, something that would be missed by all other means of

to considerable dose distortion at tissue‐air interfaces. Some early

intrafractional lung imaging, and would lead to higher toxicities or

studies have shown increased dose in lung and skin, as well as com-

under coverage of the tumor. This fast rate of tumor imaging can

promises to the accuracy of both patient plan and QA dosime-

enable MLC tracking,11 which currently relies on implanted ﬁducials

try.11,22,23

by many conventional SBRT planning systems.

and portal images that are often blocked by the MLC. Finally, an MR‐linac can provide diagnostic sequences daily, such as dynamic contrast
enhanced and diffusion weighted, to observe treatment response.12,13

2.B.2 | Technical limitations of the MR component

Observed changes in tumor volume coupled with tumor response data

The most desirable features to those early adopters might be the

can inform dose adaption, to provide the optimal curative dose.

real‐time internal imaging capability with an MR scanner. However,

As MR‐linacs become more prevalent, these advantages will be

cautions should be taken as they are not standard diagnostic MR

borne out in improved outcomes for our lung SBRT patients. Any

scanners either. First, the MR‐linac often uses lower magnetic ﬁeld

disadvantages of MR‐linacs will be eroded as the technology

strengths than diagnostic MRIs (e.g., ViewRay MRIdian uses a 0.35 T

advances. While conventional linacs have achieved excellent lung

scanner), therefore rendering compromised MR image quality. Sec-

tumor control rates, their lack of tumor imaging during treatment

ond, the limited real‐time tracking range excludes those cases with

has left us irradiating unnecessarily large volumes of normal lung tis-

very peripheral lesions. Third, real‐time target monitoring is based on

sue and chest wall. Thankfully we now have the technology to allevi-

2D MR cine images, therefore omitting the volumetric or the third‐

ate this and continue the success of lung SBRT with the MR‐linac.

dimension motion information. Fourth, the MR sequences typically
used for lung are prone to irregular breathing artifacts and banding

2.B | Dr. Dandan Zheng

artifacts.24 Fifth, in the desirable adaptive radiotherapy application,
MRI cannot provide the CT‐number information for heterogeneity

Since its clinical introduction, the MR‐linac has quite often attracted

correction which is especially important for lung SBRT dose calcula-

the spotlight as the state‐of‐the‐art treatment modality in the era of

tion. Any method to address this fundamental limitation introduces

image‐guided adaptive radiotherapy. MRI‐guidance may provide the

additional uncertainties which are more pronounced for lung

much needed breakthrough for disease sites such as pancreas, where

because lung and bone feature little MR signal.25 Last but not least,

other radiotherapy treatment modalities lack efﬁcacy due to dose‐

tissue heterogeneity in lung can induce pronounced geometric dis-

limiting normal tissue toxicity, poor on‐board x‐ray contrast, and

tortions in MR images due to local susceptibility differences, and

weak internal motion‐external surrogate correlation, etc. When it

these errors are in addition to other MR distortions such as those

comes to the titled statement for lung SBRT, however, I cannot

due to main magnetic ﬁeld and gradient ﬁeld nonlinearity.26

agree that the MR‐linac represents the best modality for reasons
elaborated below.

2.B.1 | Technical limitations of the linac component

2.B.3 | Incompatible patient populations
For the patient population with any contraindication against MRI,
the MR‐linac is not an option. These include patients with claustro-

Integrating MRI and linac poses tremendous technical challenges on

phobia and those with ferromagnetic implants such as prostheses,

both systems.14–18 While the integration has ﬁnally been made

cardiac pacemakers and deﬁbrillators, artiﬁcial heart valves, and

|
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cochlea implants. In addition, due to the bore size limitation, the

image guided radiotherapy (IGRT) (especially if multiple imaging

MR‐linac also excludes large patients and prevents the use of many

modalities are used), and gating a conventional linac SBRT lung

immobilization devices and body positions.

treatment still ends up in the same 45 min timeslot as our MR‐linac
SBRT. Technical limitations are not solely the bugbear of MR‐linacs.

2.B.4 | Alternative modalities

Conventional linacs have limited gantry and couch angles for lateral
tumors, and Cyberknife is limited in utility for posterior tumors.

Currently, there are many successful alternative modalities and tech-

While there are increased MU for off‐axis MR‐linac treatments, the

nologies for lung SBRT that the MR‐linac cannot rival. As mentioned

double stack MLC means there is no increase in leakage radiation.

previously, standard linacs are capable of delivering highly conformal

The article cited21 in fact ﬁnds no other issues with off‐axis treat-

lung SBRT plans at very high speeds with VMAT and high dose

ment. In terms of aligning the patient after imaging, commercial MR‐

rates.19 Less uncertainty and higher accuracy are further ensured

linacs either shift the couch or shift the MLC and rotational correc-

with the combinations of various imaging options (such as cone

tions are not dosimetrically important for lung SBRT.29 Electron

beam CT (CBCT), 4D CBCT, ﬂuoroscopy, and triggered MV/kV imag-

return effect is accounted for in the Monte Carlo dose planning and

ing) as well as gating or tracking mechanisms (such as external ﬁdu-

there is only an increase for skin in standard fractionation, not

cial‐ or surface‐based optical tracking and internal ﬁducial‐based

SBRT.22 The article however conﬁrms lung dose is lowered due to

radiofrequency tracking). Tumor motion can also be mitigated by

reduced margins of lung SBRT on the MR‐linac.

breath‐holding techniques such as active breathing control, compres-

Perplexingly, Dr. Zheng suggests imaging as a weakness of MR‐li-

sion techniques, and audio‐visual coaching with feedback. In addi-

nac by comparing it to diagnostic MR, rather than the low quality

tion, target dosimetry can be optimized with noncoplanar geometries

CBCT or planar kV conventional linacs rely on. MR‐linacs achieve

and 6‐degree‐of‐freedom couch corrections. Furthermore, systems

spatial accuracy of 1–2 mm in a 35 cm diameter sphere.30 Their

TM

have demonstrated extensive success using

70 cm bore allows for lateral patient shifts in order to ensure all tar-

real time tumor tracking with combined internal and external track-

gets can be within this spatially accurate region and will track well.

ing.27

Breath holds are used to ensure the 3D MR image is not affected by

such as CyberKnife

motion. While adaptive lung SBRT is not as common as other sites,

2.B.5 | Health economics

it can certainly be accomplished on the MR‐linac31 and CBCTs also
lack correct electron density. MRI has been in use since the 1970s,

MR‐linacs are expensive at a price point 2–4 times of standard linacs

as such the majority of modern medical implants have been manu-

and therefore remain questionable as a cost‐effective modality for

factured to be MR safe including all joint implants and recent

value‐based health care. Its cost could be more justiﬁed in diseases

implantable cardiac devices. With the low ﬁeld strength of MR‐linacs,

such as pancreatic cancer where the current treatment efﬁcacy is

many more are compatible. Patients undergoing any radiotherapy

poor and x‐ray based imaging does not provide sufﬁcient contrast.

can have anxiety, and are medicated as needed.

Whereas the excess cost may not be justiﬁed for lung SBRT where

My opening statement addressed the advantages of the MR‐linac

the standard treatment modalities are much more cost‐effective and

over current modalities. In particular, it mentioned the extra radiation

highly successful with >90% local control rates and low toxicity to

required for CBCT (4D!) and ﬂuoroscopy. The only modality Dr.

normal tissues, along with adequate image‐guidance and track-

Zheng discussed that could provide continuous tumor monitoring is

ing.27,28

radiofrequency tracking, but this requires an invasive procedure to

In conclusion, MR‐linac is clearly not a viable lung SBRT treat-

implant the markers. Cyberknife is limited in size and position of

ment modality for a large population of patients with contraindica-

tumors for its marker‐less tracking.32 All the other techniques are

tions. For the other patients, it is still not the best modality based

only surrogates for the tumor position. Lastly Dr. Zheng mentions

on the arguments above, as the alternative modalities provide more

cost. To the patient there is no difference in cost. The MR‐linac pur-

advanced dosimetry and delivery efﬁciency, more robust and versa-

chase cost is actually only 1–2 times a conventional linac, depending

tile image guidance and motion management approaches, clear cost‐

on how many extras like 4D CBCT, radiofrequency tracking, 6DoF

effectiveness, and well‐documented clinical success.

couch, or gating you buy in an attempt to reach the tracking ability
of the MR‐linac.

3 | REBUTTAL
3.A | Dr. Andrew Godley

In summary, the only compelling advantage of conventional
linacs is their delivery speed, but without continuous tumor tracking,
this just allows you to miss the target quicker. Hence I maintain that
MR‐linac is the best modality for lung SBRT.

I would like to thank my colleague and friend Dr. Zheng for eloquently sharing her concerns with MR‐Linac lung SBRT. I am happy
to now assuage those concerns. The ﬁrst of which is treatment time.

3.B | Dr. Dandan Zheng

While treatment delivery is the one advantage of conventional linacs,

I, too, share the vision of Dr. Godley's on the ideal radiotherapy treat-

due to the extra time required for patient setup, immobilization,

ment. But today's MR‐linac is far from the embodiment of that vision.

10
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More importantly, while the MR‐linac should be further advanced as a

MLC‐tracking and couch‐tracking,35,36 but these solutions would be

frontrunner modality toward that vision for diseases like pancreatic

difﬁcult to adopt on MR‐linacs due to the interfering magnetic ﬁeld.

cancer, it is not the case for lung SBRT. For pancreas, current radio-

The so‐called “MR‐tracking” is not really “tracking” but gating, which

therapy provides relatively poor efﬁcacy with organ toxicity partly due

substantially lengthens the treatment duration and has fallen out of

to low soft‐tissue imaging contrast, while MRI may offer the important

fashion for lung SBRT because of it. In fact, the MR‐gating may actu-

soft‐tissue contrast resolution that is superior to the competing x‐ray

ally be managing the extra motion uncertainty created by the length-

technologies. Whereas for lung, contrast is not as challenging, and cur-

ened treatment but does not necessarily improve the overall accuracy.

rent SBRT can already achieve 98% tumor control as cited by Dr. God-

The much larger (compared with the conventional ITV) MR‐ITV cre-

ley.4 As discussed above and will be stressed again below, numerous

ated with treatment‐length cine MRIs that Dr. Godley described earlier

existing technical issues in MR‐linacs make it far from being the ulti-

might serve as a proof to this.8 Since the current high tumor control

mate solution toward that vision. But even hypothetically assuming all

rate argues against the tumor underdosing using the conventional ITV

issues would have been perfectly resolved someday, arguing for the

that Dr. Godley cautioned about, I would offer another more likely rea-

MR‐linac as the best modality for lung SBRT would still be like arguing

son for the larger MRI‐ITV volumes: an effect of the increased motion

for proton therapy for prostate: Are there enough clinically meaningful

uncertainty due to the much longer “treatment length”!

gains to justify the higher cost?
Let's revisit MR‐linacs' three main advantages laid out by Dr.
Godley.

3.B.3 | Tumor monitoring
Although incapable of real‐time tumor targeting, the expensive MR‐

3.B.1 | Comfort

linac does provide the desirable real‐time tumor monitoring. However, for lungs, such monitoring capability is not unique to MRI due

With VMAT, high dose rates and fast collimators, lung SBRT treat-

to high x‐ray imaging contrast and minimally invasive ﬁducial implan-

ment delivery time can be dramatically shortened to 2–3 min on

tation procedures. Continuous x‐ray monitoring based on tumors or

standard linacs. Due to the magnetic ﬁeld, MR‐linacs pose technical

ﬁducials has long been established and achieved high precision for

limitations that lengthen the treatment by several folds. On top of

lung. Signiﬁcantly shortened treatment delivery and SBRT hypo‐frac-

that, MR‐gating can prolong treatment delivery even more. For a

tionation have further alleviated concerns about additional radiation

treatment that currently takes minutes on standard linacs and may

exposure. Meanwhile, exposure‐free radiofrequency tracking has

someday take seconds with FLASH‐RT,33 how would its hour‐long

been FDA‐approved for lung and can be integrated with real‐time

gated counterpart on MR‐linacs increase patient comfort?

MLC‐tracking.35 In addition to these mature technologies, the feasibility of other real‐time lung‐tumor monitoring has also been demon-

3.B.2 | Accuracy

strated with radiation‐dose‐free Compton‐scatter imaging using the
therapy beam37 and with PET emission guidance.38

In the opening statement Dr. Godley described, “MR‐linac provides

In summary, MR‐linacs should be better used where they are

the best targeting of any system available as it directly images the

needed. For lung SBRT, competing technologies are highly success-

tumor throughout treatment delivery.” This statement is misleading

ful, and offer higher cost‐effectiveness and better solutions.

because it assumes a huge leap of faith. Being able to “image” the
tumor real time is far from being able to “target” it real time. TG76
summarizes respiratory motion management in four main approaches:
(a) motion‐encompassing, that is, ITV; (b) respiratory gating, (c) volun-

CONFLICT OF INTEREST
No conﬂicts of interest.

tary or involuntary breath hold (including compression); and (d) real‐
time tumor‐tracking.34 Dr. Godley described MR‐tracking as real‐time
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tumor‐tracking, the most desirable approach from the above list,
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